What are the classes of diuretics and their mechanisms of action?

Types of Diuretics and Mechanisms of Action

Diuretics are classified into four main classes based on their site of action in the nephron: loop diuretics (acting at the loop of Henle), thiazide/thiazide-like diuretics (acting at the distal convoluted tubule), potassium-sparing diuretics including aldosterone antagonists (acting at the collecting duct), and carbonic anhydrase inhibitors (acting at the proximal tubule).

Loop Diuretics

Site and Mechanism: Loop diuretics (bumetanide, furosemide, torsemide) act at the thick ascending limb of the loop of Henle by blocking the Na-K-2Cl cotransporter 1, 2. This is the most potent site for sodium excretion.

Pharmacological Effects:

• Increase sodium excretion up to 20-25% of the filtered load 2
• Enhance free water clearance 2
• Maintain efficacy even with severely impaired renal function 2
• Duration of action: 4-6 hours (bumetanide), 6-8 hours (furosemide), 12-16 hours (torsemide) 1

Clinical Application: Loop diuretics are the preferred agents for most heart failure patients, particularly those with severe HF (NYHA class III-IV) or severe renal impairment (eGFR <30 mL/min) 3. They produce symptomatic benefits more rapidly than any other HF drug, relieving pulmonary and peripheral edema within hours to days 4, 2.

Important Caveat: Loop diuretics activate the renin-angiotensin-aldosterone system (RAAS) through two mechanisms: volume depletion triggers compensatory RAAS activation, and direct blockade of Na cotransporters at the macula densa stimulates renin secretion 5. This creates a vicious cycle requiring dose escalation over time.

Thiazide and Thiazide-Like Diuretics

Site and Mechanism: Thiazides (hydrochlorothiazide, chlorothiazide) and thiazide-like agents (chlorthalidone, indapamide, metolazone) inhibit the Na-Cl cotransporter in the distal convoluted tubule 1, 2.

Pharmacological Effects:

• Increase fractional sodium excretion to only 5-10% of filtered load 2
• Tend to decrease free water clearance 2
• Lose effectiveness when creatinine clearance <40 mL/min 2
• Provide more persistent antihypertensive effects than loop diuretics 1, 2
• Duration of action: 6-12 hours (hydrochlorothiazide), 24-72 hours (chlorthalidone), 36 hours (indapamide) 1

Clinical Application: Thiazides should be used for blood pressure control and volume management in hypertensive HF patients with mild fluid retention 3, 1. They are first-line agents for hypertension management 6, 7, 8. However, they are less effective than loop diuretics for volume control in severe HF 3.

Important Distinction: In the ALLHAT trial, chlorthalidone demonstrated superior outcomes compared to other agents 3. More recent data from a pragmatic trial showed that switching from hydrochlorothiazide to chlorthalidone did not lower MACE rates in the general population, though patients with established ASCVD showed greater benefit with chlorthalidone 7.

Potassium-Sparing Diuretics and Aldosterone Antagonists

Site and Mechanism: These agents act at the collecting duct through different mechanisms:

• Aldosterone antagonists (spironolactone, eplerenone): Block mineralocorticoid receptors 3, 1
• Epithelial sodium channel blockers (amiloride, triamterene): Directly block sodium channels 1

Pharmacological Effects:

• Weak diuretic effect when used alone
• Prevent potassium loss
• Duration of action: 1-3 hours (spironolactone), 24 hours (amiloride, eplerenone) 1

Clinical Application: Aldosterone antagonists (spironolactone, eplerenone) have proven mortality benefit in HF with reduced ejection fraction (EF <40%) and should be included in the regimen for NYHA class II-IV patients 3. They are particularly effective as add-on therapy in resistant hypertension 3, 8.

Critical Safety Parameters: Do NOT use if:

• Serum creatinine ≥2.5 mg/dL (men) or ≥2.0 mg/dL (women)
• Serum potassium ≥5.0 mEq/L 3

When combined with ACE inhibitors or ARBs, monitor potassium frequently 3. Spironolactone carries higher risk of gynecomastia and impotence compared to eplerenone 6.

Carbonic Anhydrase Inhibitors

Site and Mechanism: Act at the proximal tubule by inhibiting carbonic anhydrase, reducing sodium and bicarbonate reabsorption 9, 10.

Clinical Application: These agents have limited use as diuretics in cardiovascular disease. Their primary indication is glaucoma treatment 10. They are not routinely recommended for heart failure or hypertension management.

Sequential Nephron Blockade (Combination Diuretic Therapy)

When single-agent diuretics fail to achieve adequate decongestion, combining agents that act at different nephron sites can overcome diuretic resistance 1:

• Metolazone + loop diuretic: Most commonly used combination
• Hydrochlorothiazide + loop diuretic
• Chlorothiazide IV + loop diuretic 1

This strategy is particularly useful in severe heart failure or when diuretic resistance develops 11, 12.

Key Clinical Principles

Diuretic Selection Algorithm:

1. Mild fluid retention + hypertension: Start with thiazide-type diuretic 3, 1, 2
2. Moderate-severe HF or renal impairment (eGFR <30): Use loop diuretic 3, 1
3. HF with reduced EF: Add aldosterone antagonist to loop diuretic + ACE inhibitor/ARB + beta-blocker 3, 1
4. Resistant hypertension: Add aldosterone antagonist to existing regimen 3, 8
5. Diuretic resistance: Consider sequential nephron blockade 1

Common Pitfalls to Avoid:

• Using inappropriately low diuretic doses leads to persistent fluid retention 1
• Using inappropriately high doses causes volume contraction, hypotension, and renal insufficiency 1
• Combining drugs from the same class or with similar mechanisms (e.g., ACE inhibitor + ARB + renin inhibitor) increases harm without benefit 6, 7
• Prescribing aldosterone antagonists with significant renal dysfunction or hyperkalemia 3
• Long-term diuretic use without objective congestion may cause hypotension, electrolyte disturbances, and neurohormonal activation 12, 13

Monitoring Requirements:

• Daily weights and volume status
• Serum electrolytes (especially potassium and magnesium)
• Renal function (creatinine, eGFR)
• Blood pressure
• Urine sodium can guide diuretic response in decompensated HF 5

Deprescribing Consideration: Once euvolemia is achieved and maintained, consider reducing or discontinuing diuretics with close monitoring, as long-term use without clear indication increases adverse events 12, 13. This should be gradual, individualized, and reversible with explicit thresholds for restarting treatment.